The PERSIST-1 trial compares best available treatment (BAT) with the JAK2 inhibitor pacritinib in patients with myelofibrosis. During the 2015 EHA meeting in Vienna, Dr. Ruben Mesa (Mayo Clinic, Scottsdale, Arizona, US) presented the patient reported outcomes of this trial.
(BELG J HEMATOL 2015;6(3):119–20)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
